If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Portal venous systems A portal venous system is a series of veins or venules that directly connect two capillary beds. The two systems in verebrates are the hepatic portal system, and the hypophyseal portal system.
== Organisms and discovery == Creatinase was first identified by Roche, Lacombe, & Girard in 1950 in Pseudomonas eisenbergii and P. ovalis. It is produced by other bacterial genera including Bacillus, Flavobacterium, Micrococcus, Alcaligenes, Clostridium, Arthrobacter, and Paracoccus, and is produced by other species of Pseudomonas as well. In P. putida, creatinase is coded for by the creA gene and enables growth on creatine as the sole nitrogen source. Expression of creA is regulated by CahR, an AraC/GAT-R regulator that activates gene expression in the presence of creatine. This gene has also been cloned into Escherichia coli.
The oxygenase reaction of RuBisCO may prevent CO2 depletion near its active sites and contributes to the regulation of CO2 concentration in the atmosphere The photorespiratory pathway is a major source of hydrogen peroxide (H2O2) in photosynthetic cells. Through H2O2 production and pyrimidine nucleotide interactions, photorespiration makes a key contribution to cellular redox homeostasis. In so doing, it influences multiple signalling pathways, in particular, those that govern plant hormonal responses controlling growth, environmental and defense responses, and programmed cell death. It has been postulated that photorespiration may function as a "safety valve", preventing the excess of reductive potential coming from an overreduced NADPH-pool from reacting with oxygen and producing free radicals (oxidants), as these can damage the metabolic functions of the cell by subsequent oxidation of membrane lipids, proteins or nucleotides. The mutants deficient in photorespiratory enzymes are characterized by a high redox level in the cell, impaired stomatal regulation, and accumulation of formate.
== Management == Primary treatment is prompted by the administration of adequate doses of either the thyroid hormone L-thyroxine given intravenously or by giving liothyronine via a nasogastric tube. It is essential to identify and treat the condition precipitating the coma. Myxedema coma is rare but often fatal. It occurs most often in elderly women and may be mistaken for one of the chronic debilitating diseases common to this age group. Gabrilove et al demonstrated that histological skin changes can be observed within 3-4 weeks after initiating thyroid hormone replacement therapy with desiccated thyroid extract. This was documented through skin biopsies performed on individuals with hypothyroidism both before and after treatment. The magnitude of these effects was related to the dose of thyroid hormone administered, and the rate at which this occurred depended on the amounts of material present at the outset. Though the exact cause of myxedema is still unclear, a wealth of research has demonstrated the importance of iodine. In an important study the researchers showed that in the myxedematous type of cretinism treatment with iodine normalizes thyroid function provided that the treatment is begun early in the postnatal period. If not, the prognosis remains dismal.
Sources: en.wikipedia.org
== Tissue distribution == RNA expression charts show highest expression in lung and adipose tissue in humans. Cell types that express the highest levels of CALCRL include oligodendrocyte precursor cells, endothelial cells, lymphatic endothelial cells, adipocytes, endometrial stromal cells, as well as dendritic cells.
== Diagnosis == Typical scleroderma is classically defined as symmetrical skin thickening, with about 70% of cases also presenting with Raynaud's phenomenon, nail-fold capillary changes, and antinuclear antibodies. Affected individuals may experience systemic organ involvement. No single test for scleroderma works all of the time; hence, diagnosis is often a matter of exclusion. Atypical scleroderma may show any variation of these changes without skin changes or with finger swelling only. Laboratory testing can show antitopoisomerase antibodies, like anti-scl70 (causing a diffuse systemic form), or anticentromere antibodies (causing a limited systemic form and the CREST syndrome). Other autoantibodies can be seen, such as anti-U3 or anti-RNA polymerase. Antidouble-stranded DNA autoantibodies are likely to be present in serum.
with TA the total concentration of species A. Note that it is customary to omit the ionic charges when writing and using these equations. When the equilibrium constants are known and the total concentrations are specified there are two equations in two unknown "free concentrations" [A] and [H]. This follows from the fact that [HA] = β1[A] [H], [H2A] = β2[A] [H]2 and [OH] = Kw[H]−1
The bolide impact hypothesis, first brought to wide attention in 1980 by Walter Alvarez, Luis Alvarez, and colleagues, attributes the K-Pg extinction event to a bolide (extraterrestrial projectile) impact. Alvarez and colleagues proposed that a sudden increase in iridium levels, recorded around the world in rock deposits at the Cretaceous–Paleogene boundary, was direct evidence of the impact. Shocked quartz, indicative of a strong shockwave emanating from an impact, was also found worldwide. The actual impact site remained elusive until a crater measuring 180 km (110 mi) wide was discovered in the Yucatán Peninsula of southeastern Mexico, and was publicized in a 1991 paper by Alan Hildebrand and colleagues. Now, the bulk of the evidence suggests that a bolide 5 to 15 kilometers (3 to 9+1⁄2 miles) wide impacted the Yucatán Peninsula 66 million years ago, forming this crater and creating a "kill mechanism" that triggered the extinction event. Within hours, the Chicxulub impact would have created immediate effects such as earthquakes, tsunamis, and a global firestorm that likely killed unsheltered animals and started wildfires. However, it would also have had longer-term consequences for the environment. Within days, sulfate aerosols released from rocks at the impact site would have contributed to acid rain and ocean acidification.
=== 1.2 === DisplayPort version 1.2 was introduced on 7 January 2010. The most significant improvement of this version is the doubling of the data rate to 17.28 Gbit/s in High Bit Rate 2 (HBR2) mode, which allows increased resolutions, higher refresh rates, and greater color depth, such as 3840 × 2160 at 60 Hz 10 bpc RGB. Other improvements include multiple independent video streams (daisy-chain connection with multiple monitors) called Multi-Stream Transport (MST), facilities for stereoscopic 3D, increased AUX channel bandwidth (from 1 Mbit/s to 720 Mbit/s), more color spaces including xvYCC, scRGB, and Adobe RGB 1998, and Global Time Code (GTC) for sub 1 μs audio/video synchronisation. Also Apple Inc.'s Mini DisplayPort connector, which is much smaller and designed for laptop computers and other small devices, is compatible with the new standard.
Sources: en.wikipedia.org
== Mechanism of action == Phenobarbital acts as an allosteric modulator which extends the amount of time the chloride ion channel is open by interacting with GABAA receptor subunits. Through this action, phenobarbital increases the flow of chloride ions into the neuron which decreases the excitability of the post-synaptic neuron. Hyperpolarizing this post-synaptic membrane leads to a decrease in the general excitatory aspects of the post-synaptic neuron. By making it harder to depolarize the neuron, the threshold for the action potential of the post-synaptic neuron will be increased. Direct blockade of glutamatergic AMPA and kainate receptors are also believed to contribute to the hypnotic and anticonvulsant effect that is observed with phenobarbital.
== Donation to Yadadri temple == On behalf of the Nizam Family, she donated a gold chain worth Rs 6 lakh to the Sri Lakshmi Narasimha Swamy Temple, Yadadri. The gold necklace was handed over to the temple Executive Officer Geetha by Yadagirigutta Temple Development Authority (YTDA) vice-chairman Kishan Rao.
Florey returned to the UK in October 1944, collecting his children from Fulton while en route. He was created a Knight Bachelor on 8 June 1944, and invested by King George VI at Buckingham Palace on 4 July 1944. He shared the Nobel Prize in Physiology or Medicine in 1945 with Chain and Fleming. Fleming first observed the antibiotic properties of the mould that makes penicillin, but it was Chain and Florey who developed it into a useful treatment. Isolation of the active compound from the mould depended crucially on Heatley's technical contributions, and for his part, he was awarded an honorary Doctorate of Medicine by Oxford University in 1990. Florey maintained that the penicillin project was originally driven by scientific interests, and that the medicinal discovery was a bonus. The neuroscientist W. Maxwell Cowan observed that: Fleming was the first person Florey saved. Without Florey's work he would have gone down as a somewhat eccentric microbiologist. Florey always insisted that the development of penicillin was a team effort and that he received more credit than he deserved, but the team itself was his creation. The philanthropist Lord Nuffield offered Florey £50,000 (equivalent to £1,866,000 in 2025) as a personal gift; Florey asked him instead to use it to establish research fellowships at the Sir William Dunn School. The first beneficiaries included Abraham, Heatley and Sanders.
t is age of the sample, D* is number of atoms of the radiogenic daughter isotope in the sample, D0 is number of atoms of the daughter isotope in the original or initial composition, N(t) is number of atoms of the parent isotope in the sample at time t (the present), given by N(t) = N0e−λt, and λ is the decay constant of the parent isotope, equal to the inverse of the radioactive half-life of the parent isotope times the natural logarithm of 2. The equation is most conveniently expressed in terms of the measured quantity N(t) rather than the constant initial value No. To calculate the age, it is assumed that the system is closed (neither parent nor daughter isotopes have been lost from system), D0 either must be negligible or can be accurately estimated, λ is known to high precision, and one has accurate and precise measurements of D* and N(t). The above equation makes use of information on the composition of parent and daughter isotopes at the time the material being tested cooled below its closure temperature. This is well established for most isotopic systems. However, construction of an isochron does not require information on the original compositions, using merely the present ratios of the parent and daughter isotopes to a standard isotope. An isochron plot is used to solve the age equation graphically and calculate the age of the sample and the original composition.
=== Pharmacokinetics === Metformin has an oral bioavailability of 50–60% under fasting conditions, and is absorbed slowly. Peak plasma concentrations (Cmax) are reached within 1–3 hours of taking immediate-release metformin and 4–8 hours with extended-release formulations. The plasma protein binding of metformin is negligible, as reflected by its very high apparent volume of distribution (300–1000 L after a single dose). Steady state is usually reached in 1–2 days. Metformin has acid dissociation constant values (pKa) of 2.8 and 11.5, so it exists very largely as the hydrophilic cationic species at physiological pH values. The metformin pKa values make it a stronger base than most other basic medications with less than 0.01% nonionized in blood. Furthermore, the lipid solubility of the nonionized species is slight as shown by its low logP value (log(10) of the distribution coefficient of the nonionized form between octanol and water) of −1.43. These chemical parameters indicate low lipophilicity and, consequently, rapid passive diffusion of metformin through cell membranes is unlikely. As a result of its low lipid solubility, it requires the transporter SLC22A1 for it to enter cells. The logP of metformin is less than that of phenformin (−0.84) because two methyl substituents on metformin impart lesser lipophilicity than the larger phenylethyl side chain in phenformin. More lipophilic derivatives of metformin are presently under investigation to produce prodrugs with superior oral absorption than metformin. Metformin is not metabolized.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.